Inhibrx Funding: How Much Did They Raise & Key Investors

How Much Did Inhibrx Raise?
Funding & Key Investors

Inhibrx Biosciences has solidified its position within the competitive biopharmaceutical landscape, securing a total capital infusion of $21M. This trajectory of financial backing, punctuated by a recent strategic investment of $1M, underscores the market confidence in the firm's specialized approach to biologic therapeutics. By leveraging these resources, the company continues to advance its clinical-stage pipeline, targeting high-unmet-need conditions through sophisticated molecular engineering.

The firm's ability to attract significant financing reflects its operational maturity and the potential of its proprietary therapeutic candidates. As the company navigates the complexities of clinical trials, this influx of capital serves as a critical catalyst for accelerating research and development initiatives, ensuring that its innovative candidates move efficiently through the regulatory and clinical pipeline.

What is Inhibrx?

Inhibrx

Manufacturing

Business Services

Research & Development

Inhibrx Biosciences, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the development of novel biologic therapeutics. The company focuses on addressing life-threatening conditions through a robust pipeline that includes candidates such as INBRX-109 and INBRX-106. These assets utilize advanced tetravalent and hexavalent single-domain antibody (sdAb) platforms to target specific pathways, including death-receptor 5 and OX4. Based in La Jolla, California, the organization maintains a strategic focus on oncology, specifically targeting challenging indications like chondrosarcoma, non-small cell lung cancer, and various gastroesophageal malignancies. By integrating cutting-edge protein engineering with rigorous clinical validation, Inhibrx Biosciences aims to redefine treatment paradigms for patients facing limited therapeutic options.

How much funding has Inhibrx raised?

Inhibrx has raised a total of $21M across 2 funding rounds:

2015

Debt

$20M

2020

Debt

$1M

Debt (2015): $20M with participation from Oxford Finance

Debt (2020): $1M led by PPP

Key Investors in Inhibrx

Oxford Finance

Oxford Finance is a specialty finance firm providing flexible capital solutions tailored to the unique needs of healthcare and life sciences organizations.

PPP

Public-Private Partnership

What's next for Inhibrx?

Looking ahead, the strategic deployment of the $1M will likely center on the progression of Phase 2 clinical trials and the potential expansion of the therapeutic portfolio. The company is positioned to leverage its current financial stability to enhance its research infrastructure and potentially pursue collaborative partnerships that could expedite the commercialization of its lead candidates. As the biopharmaceutical sector continues to prioritize precision medicine, Inhibrx Biosciences is well-situated to capitalize on its unique technological platform, provided it maintains its current momentum in clinical execution and regulatory compliance. Future milestones will likely involve data readouts from ongoing trials, which will serve as key indicators for the company's long-term valuation and market impact.

See full Inhibrx company page

See More Financial Insights